Science News
from research organizations

Move over Prozac: New drug offers hope for depression

Date:
April 24, 2011
Source:
Journal of Clinical Investigation
Summary:
The brain chemistry that underlies depression is incompletely understood, but research suggests that aberrant signaling by a chemical called brain-derived neurotrophic factor through its receptor TrkB, may contribute to anxiety and depression. Here, researchers describe a screen for stable small molecules that could specifically inhibit TrkB action. They identified one they dubbed ANA-12, which had potent behavioral effects when administered to mice that suggest it will have antidepressant and anti-anxiety activity in humans.
Share:
       
FULL STORY

The brain chemistry that underlies depression is incompletely understood, but research suggests that aberrant signaling by a chemical called Brain-Derived Neurotrophic Factor through its receptor TrkB, may contribute to anxiety and depression. Here, researchers describe a screen for stable small molecules that could specifically inhibit TrkB action. They identified one they dubbed ANA-12, which had potent behavioral effects when administered to mice that suggest it will have antidepressant and anti-anxiety activity in humans.

An estimated 19 million Americans suffer from depression, and though the symptoms might be recognizable, the brain chemistry that underlies them is incompletely understood. Research suggests that aberrant signaling by a chemical called Brain-Derived Neurotrophic Factor (BDNF) through its receptor TrkB, may contribute to anxiety and depression, and inhibiting this pathway in mice can reduce anxiety and depression-related behaviors. However, translating these findings to clinical studies will require the development of small molecule inhibitors of the BDNF/TrkB pathway that could be used pharmacologically.

In this paper, researchers led by Maxime Cazorla, of Columbia University in New York, and Didier Rognan, of the Université de Strasbourg in France, describe a screen for stable small molecules that could specifically inhibit TrkB action. They identified one they dubbed ANA-12, which had potent behavioral effects when administered to mice that suggest it will have antidepressant and anti-anxiety activity in humans. The researchers are hopeful that this new compound could be used to develop a new class of psychiatric drugs.


Story Source:

The above post is reprinted from materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Maxime Cazorla, Joël Prémont, Andre Mann, Nicolas Girard, Christoph Kellendonk, Didier Rognan. Identification of a low–molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. Journal of Clinical Investigation, 2011; DOI: 10.1172/JCI43992

Cite This Page:

Journal of Clinical Investigation. "Move over Prozac: New drug offers hope for depression." ScienceDaily. ScienceDaily, 24 April 2011. <www.sciencedaily.com/releases/2011/04/110418122314.htm>.
Journal of Clinical Investigation. (2011, April 24). Move over Prozac: New drug offers hope for depression. ScienceDaily. Retrieved June 30, 2015 from www.sciencedaily.com/releases/2011/04/110418122314.htm
Journal of Clinical Investigation. "Move over Prozac: New drug offers hope for depression." ScienceDaily. www.sciencedaily.com/releases/2011/04/110418122314.htm (accessed June 30, 2015).

Share This Page: